scPharmaceuticals (SCPH) Company Report

Scilex Holding Company has secured a worldwide exclusive license from Datavault AI for its AI-driven technology to create and operate a Biotech Exchange platform.
This platform is intended to enable the secure tokenization, trading, and monetization of biotech assets, including genomic, DNA data, diagnostic, therapeutic products, genetic, and drug information.
The licensing agreement includes a non-refundable upfront license fee totaling $10 million, payable in four equal installments of $2.5 million through September 2026.
Datavault AI is also eligible for sales milestone payments of up to an aggregate of $2.55 billion upon the achievement of certain sales milestones.
Scilex believes there is an opportunity to tokenize approximately $2.0 trillion in pharmaceutical drug and diagnostic sales through this platform.

Nov 4, 2025, 11:00 AM

scPharmaceuticals Inc. Acquired by MannKind Corporation

SCPH

M&A

Delisting/Listing Issues

Board Change

scPharmaceuticals Inc. (SCPH) was acquired by MannKind Corporation on October 7, 2025, becoming a direct wholly owned subsidiary.
Shareholders received $5.35 in cash and one non-tradable contingent value right (CVR) per share, with CVRs potentially yielding up to an additional $1.00.
Following the acquisition, SCPH shares were delisted from The Nasdaq Global Select Market, and trading was halted on October 7, 2025.
The company's Board of Directors resigned, and a new management team was appointed, including Michael E. Castagna as President and Chief Executive Officer, and Chris Prentiss as Chief Financial Officer of the surviving corporation.
Key agreements, including the Credit Agreement and Guaranty and the Revenue Participation Right Purchase and Sale Agreement, were terminated in connection with the merger.

Oct 7, 2025, 1:18 PM

scPharmaceuticals Acquisition by MannKind Completed

SCPH

M&A

Revenue Acceleration/Inflection

Delisting/Listing Issues

MannKind Corporation completed the acquisition of scPharmaceuticals Inc. on October 7, 2025, making scPharmaceuticals a wholly owned subsidiary.
The acquisition is expected to diversify and accelerate MannKind’s double-digit revenue growth, driven by the innovative therapy FUROSCIX®.
The transaction was valued at $5.35 per share in cash plus one non-tradable contingent value right (CVR) per share for up to an aggregate of $1.00 per CVR in cash, totaling up to $6.35 per share.
As of October 7, 2025, scPharmaceuticals' common stock ceased trading and was delisted from Nasdaq.

Oct 7, 2025, 1:02 PM

scPharmaceuticals Investigated by Halper Sadeh LLC Regarding Sale to MannKind Corporation

SCPH

M&A

Legal Proceedings

Takeover Bid

Halper Sadeh LLC is investigating scPharmaceuticals Inc. (NASDAQ: SCPH) for potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders.
The investigation relates to scPharmaceuticals Inc.'s proposed sale to MannKind Corporation.
Under the terms of the proposed transaction, scPharmaceuticals shareholders would receive a cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share, with the CVR potentially worth up to an additional $1.00 in cash.

Sep 16, 2025, 3:40 PM

Earnings Transcripts

Quarterly earnings call transcripts for scPharmaceuticals.

Get instant answers from SEC filings, earnings calls & more

Get instant analysis when filings drop